A unique new flexible and stretchable device, worn against the skin and capable of producing electrical energy by transforming the compounds present in sweat, was recently developed and patented by CNRS researchers from l’Université Grenoble Alpes and UC San Diego (USA). This cell is already capable of continuously lighting an LED, opening new avenues for the development of wearable electronics powered by autonomous and environmentally friendly biodevices.
This research was published in Advanced Functional Materials on September 25, 2019.
The potential uses for wearable electronic devices continue to increase, especially for medical and athletic monitoring. Such devices require the development of a reliable and efficient energy source that can easily be integrated into the human body. Using “biofuels” present in human organic liquids has long been a promising avenue.
Scientists from the Département de chimie moléculaire (CNRS/Université Grenoble Alpes), who specialize in bioelectrochemistry, decided to collaborate with an American team from UC San Diego, who are experts in nanomachines, biosensors, and nanobioelectronics. Together they developed a flexible conductive material consisting of carbon nanotubes, crosslinked polymers, and enzymes joined by stretchable connectors that are directly printed onto the material through screen-printing1.
The biofuel cell, which follows deformations in the skin, produces electrical energy through the reduction of oxygen and the oxidation of the lactate present in perspiration.
Once applied to the arm, it uses a voltage booster to continuously power an LED. It is relatively simple and inexpensive to produce, with the primary cost being the production of the enzymes that transform the compounds found in sweat. The researchers are now seeking to amplify the voltage provided by the biofuel cell in order to power larger portable devices.
The Latest on: Biofuel cell
via Google News
The Latest on: Biofuel cell
- Vaxart and Kindred Bio expand manufacturing agreement for COVID-19 vaccine candidateson October 7, 2020 at 5:29 am
Vaxart (NASDAQ:VXRT) and Centaur Biopharmaceutical Services, a subsidiary of Kindred Biosciences (NASDAQ:KIN) have expanded their agreement under which Centaur will manufacture Vaxart's oral vaccine ...
- A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipelineon October 7, 2020 at 3:36 am
More than 15 years after beating cancer himself, A2 Biotherapeutics CEO Scott Foraker has pulled in a $71.5 million Series B round to send a mystery candidate for solid tumors into the clinic.
- New Bio-Inspired Molecule Helps Concrete Resist Freeze Damageon October 7, 2020 at 12:17 am
Daily temperature swings can make water freeze and expand, then thaw and contract. Because concrete is porous and absorbs liquid, these changes often make its surface flake and peel. But researchers ...
- Mustang Bio in-licenses vector-enhancing technology for gene therapyon October 6, 2020 at 6:19 am
Mustang Bio (NASDAQ:MBIO) inks an agreement with SIRION Biotech GmbH securing rights to the latter's LentiBOOST technology for the development of MB-207, a gene therapy for X-linked severe combined ...
- Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugson October 6, 2020 at 4:33 am
Scientists at microbiome therapy developers often talk about the importance of community, how the bugs in our gut act in concert in addition to ...
- Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesaon October 6, 2020 at 4:11 am
(GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced ...
- Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccineon October 5, 2020 at 9:23 pm
Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301. Researchers from HDT Bio and the University ...
- Cell Isolation Market to reach USD 9.47 bn by 2024, Agilent Technologies Inc. and Becton, Dickinson and Co. emerge as Key Contributors to Growth| Technavioon October 5, 2020 at 8:30 pm
Technavio has been monitoring the cell isolation market and it is poised to grow by USD 9.47 bn during 2020-2024, progressing at a CAGR of almost 21% during the forecast period. The report offers an ...
- Generation Bio to Present at 2020 Virtual Cell & Gene Meeting on the Mesaon October 5, 2020 at 3:42 am
Geoff McDonough, M.D., Generation Bio’s president and chief executive officer, will participate in a panel on the future of gene delivery. That discussion will be available to view on demand on the ...
- Adicet Bio to Present at the Jefferies Cell Therapy Summiton October 1, 2020 at 1:10 pm
(GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen ...
via Bing News